{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T02:49:05Z","timestamp":1793155745681,"version":"4.5.0"},"reference-count":341,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,6,1]],"date-time":"2026-06-01T00:00:00Z","timestamp":1780272000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,12,21]],"date-time":"2025-12-21T00:00:00Z","timestamp":1766275200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000265","name":"UK Research and Innovation Medical Research Council","doi-asserted-by":"publisher","award":["MR\/X014010\/1"],"award-info":[{"award-number":["MR\/X014010\/1"]}],"id":[{"id":"10.13039\/501100000265","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Pharmaceutics: X"],"published-print":{"date-parts":[[2026,6]]},"DOI":"10.1016\/j.ijpx.2025.100478","type":"journal-article","created":{"date-parts":[[2025,12,24]],"date-time":"2025-12-24T00:19:43Z","timestamp":1766535583000},"page":"100478","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"C","title":["Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges"],"prefix":"10.1016","volume":"11","author":[{"given":"Hussein T.","family":"Kenaan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ross M.","family":"Duncan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wafa T.","family":"Al-Jamal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David S.","family":"Jones","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gavin P.","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brendan","family":"Gilmore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vanessa","family":"Yardley","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicola","family":"Farrington","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine E.","family":"Stott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"David","family":"Lawrence","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joseph N.","family":"Jarvis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas S.","family":"Harrison","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen","family":"Robinson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Isabela","family":"Ribeiro","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William","family":"Hope","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yiwei","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijpx.2025.100478_bb0005","doi-asserted-by":"crossref","first-page":"658","DOI":"10.1093\/jbcr\/irz060","article-title":"Bacteriologic profile of burn wounds at a Tertiary Government Hospital in the Philippines\u2014UP-PGH ATR burn center","volume":"40","author":"Abesamis","year":"2019","journal-title":"J. Burn Care Res."},{"key":"10.1016\/j.ijpx.2025.100478_bb0010","doi-asserted-by":"crossref","first-page":"21","DOI":"10.1093\/jac\/49.suppl_1.21","article-title":"AmBisome: liposomal formulation, structure, mechanism of action and pre-clinical experience","volume":"49","author":"Adler-Moore","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb0015","doi-asserted-by":"crossref","first-page":"S244","DOI":"10.1093\/cid\/ciz064","article-title":"Preclinical safety, tolerability, pharmacokinetics, pharmacodynamics, and antifungal activity of liposomal Amphotericin B","volume":"68","author":"Adler-Moore","year":"2019","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpx.2025.100478_bb0020","doi-asserted-by":"crossref","first-page":"429","DOI":"10.3109\/08982109309150729","article-title":"Development, characterization, efficacy and mode of action of Ambisome, A Unilamellar liposomal formulation of Amphotericin B","volume":"3","author":"Adler-Moore","year":"1993","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ijpx.2025.100478_bb0025","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1111\/j.1469-0691.2008.01979.x","article-title":"Amphotericin B lipid preparations: what are the differences?","volume":"14","author":"Adler-Moore","year":"2008","journal-title":"Clin. Microbiol. Infect."},{"key":"10.1016\/j.ijpx.2025.100478_bb0030","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1093\/mmy\/myv111","article-title":"Comparison between liposomal formulations of amphotericin B","volume":"54","author":"Adler-Moore","year":"2016","journal-title":"Med. Mycol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0035","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1080\/1061186X.2018.1527337","article-title":"Liposome: composition, characterisation, preparation, and recent innovation in clinical applications","volume":"27","author":"Ahmed","year":"2019","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ijpx.2025.100478_bb0040","article-title":"Amphotericin B in the Era of New Antifungals: where will it stand?","volume":"10","author":"Akinosoglou","year":"2024","journal-title":"J. Fungi (Basel)"},{"key":"10.1016\/j.ijpx.2025.100478_bb0045","doi-asserted-by":"crossref","first-page":"2694","DOI":"10.1128\/AAC.00235-13","article-title":"Efficacy and safety of liposomal clarithromycin and its effect on Pseudomonas aeruginosa virulence factors","volume":"57","author":"Alhajlan","year":"2013","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb0050","doi-asserted-by":"crossref","first-page":"6949","DOI":"10.2147\/IJN.S141709","article-title":"Efficacy of neutral and negatively charged liposome-loaded gentamicin on planktonic bacteria and biofilm communities","volume":"12","author":"Alhariri","year":"2017","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijpx.2025.100478_bb0055","doi-asserted-by":"crossref","first-page":"409","DOI":"10.4155\/tde.14.13","article-title":"Liposomal antibiotic formulations for targeting the lungs in the treatment of Pseudomonas Aeruginosa","volume":"5","author":"Alipour","year":"2014","journal-title":"Ther. Deliv."},{"key":"10.1016\/j.ijpx.2025.100478_bb0060","doi-asserted-by":"crossref","first-page":"293","DOI":"10.1016\/j.ijpharm.2007.11.035","article-title":"Antimicrobial effectiveness of liposomal polymyxin B against resistant Gram-negative bacterial strains","volume":"355","author":"Alipour","year":"2008","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb0065","doi-asserted-by":"crossref","first-page":"747","DOI":"10.2165\/00003495-199856050-00001","article-title":"Liposomal drug formulations","volume":"56","author":"Allen","year":"1998","journal-title":"Drugs"},{"key":"10.1016\/j.ijpx.2025.100478_bb0070","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14050960","article-title":"Liposome-Encapsulated Tobramycin and IDR-1018 peptide mediated biofilm disruption and enhanced antimicrobial activity against Pseudomonas aeruginosa","volume":"14","author":"Alzahrani","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2025.100478_bb0075","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1124\/pharmrev.120.000108","article-title":"Inhaled medicines: past, present, and future","volume":"74","author":"Anderson","year":"2022","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.ijpx.2025.100478_bb0080","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nchembio.1496","article-title":"Amphotericin forms an extramembranous and fungicidal sterol sponge","volume":"10","author":"Anderson","year":"2014","journal-title":"Nat. Chem. Biol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0085","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1002\/9780470259818.ch13","article-title":"Liposomes and Drug delivery","author":"Antimisiaris","year":"2008","journal-title":"Pharmaceut. Manufact. Handb."},{"key":"10.1016\/j.ijpx.2025.100478_bb0090","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1080\/10837450.2017.1290106","article-title":"Development of a novel one-step production system for injectable liposomes under GMP","volume":"23","author":"Araki","year":"2018","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0095","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1038\/s41579-018-0019-y","article-title":"Implant infections: adhesion, biofilm formation and immune evasion","volume":"16","author":"Arciola","year":"2018","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0100","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/j.1439-0507.1995.tb00020.x","article-title":"Infusion-related toxicity of three different amphotericin B formulations and its relation to cytokine plasma levels","volume":"38","author":"Arning","year":"1995","journal-title":"Mycoses"},{"key":"10.1016\/j.ijpx.2025.100478_bb0105","doi-asserted-by":"crossref","first-page":"1423","DOI":"10.3109\/13880209.2014.895018","article-title":"Eradication of methicillin-resistant Staphylococcus aureus infection by nanoliposomes loaded with gentamicin and oleic acid","volume":"52","author":"Atashbeyk","year":"2014","journal-title":"Pharm. Biol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0110","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1186\/s40360-019-0302-1","article-title":"Safety and effectiveness of low-dose amikacin in nontuberculous mycobacterial pulmonary disease treated in Toronto, Canada","volume":"20","author":"Aznar","year":"2019","journal-title":"BMC Pharmacol. Toxicol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0115","doi-asserted-by":"crossref","first-page":"3842","DOI":"10.1039\/D1GC00097G","article-title":"Self-assembly, interfacial properties, interactions with macromolecules and molecular modelling and simulation of microbial bio-based amphiphiles (biosurfactants). A tutorial review","volume":"23","author":"Baccile","year":"2021","journal-title":"Green Chem."},{"key":"10.1016\/j.ijpx.2025.100478_bb0120","series-title":"Molecular Medical Microbiology (Third Edition)","first-page":"2921","article-title":"Chapter 148 - Pathogenesis of protozoan infections","author":"Baig","year":"2024"},{"key":"10.1016\/j.ijpx.2025.100478_bb0125","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1093\/infdis\/171.4.938","article-title":"Efficacy of gentamicin or ceftazidime entrapped in liposomes with prolonged blood circulation and enhanced localization in Klebsiella pneumoniae-infected lung tissue","volume":"171","author":"Bakker-Woudenberg","year":"1995","journal-title":"J. Infect. Dis."},{"key":"10.1016\/j.ijpx.2025.100478_bb0130","series-title":"Long-circulating sterically stabilized liposomes in the treatment of infections, methods in enzymology","first-page":"228","author":"Bakker-Woudenberg","year":"2005"},{"key":"10.1016\/j.ijpx.2025.100478_bb0135","first-page":"6","article-title":"Antimicrobials from actinomycetes : back to the future","volume":"2","author":"Baltz","year":"2007","journal-title":"Microbe"},{"key":"10.1016\/j.ijpx.2025.100478_bb0140","doi-asserted-by":"crossref","first-page":"1825","DOI":"10.1093\/jac\/dkz147","article-title":"Spanish nationwide survey on Pseudomonas aeruginosa antimicrobial resistance mechanisms and epidemiology","volume":"74","author":"del Barrio-Tofi\u00f1o","year":"2019","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb0145","doi-asserted-by":"crossref","DOI":"10.1155\/2016\/4065603","article-title":"Multidrug resistant and extensively drug resistant bacteria: a study","volume":"2016","author":"Basak","year":"2016","journal-title":"J. Pathogens"},{"key":"10.1016\/j.ijpx.2025.100478_bb0150","doi-asserted-by":"crossref","first-page":"105","DOI":"10.1021\/cb3005116","article-title":"Aminoglycoside Antibiotics in the 21st Century","volume":"8","author":"Becker","year":"2013","journal-title":"ACS Chem. Biol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.jconrel.2018.02.040","article-title":"Towards clinical translation of ligand-functionalized liposomes in targeted cancer therapy: challenges and opportunities","volume":"277","author":"Belfiore","year":"2018","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2025.100478_bb0160","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1007\/s15010-017-1042-z","article-title":"Pharmacokinetics of antifungal drugs: practical implications for optimized treatment of patients","volume":"45","author":"Bellmann","year":"2017","journal-title":"Infection"},{"key":"10.1016\/j.ijpx.2025.100478_bb0165","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1093\/jac\/dkh542","article-title":"Liposomal amphotericin B activates antifungal resistance with reduced toxicity by diverting Toll-like receptor signalling from TLR-2 to TLR-4","volume":"55","author":"Bellocchio","year":"2005","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb0170","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1186\/s12645-019-0055-y","article-title":"Nanomedicine review: clinical developments in liposomal applications","volume":"10","author":"Beltr\u00e1n-Gracia","year":"2019","journal-title":"Cancer Nanotechnol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0175","doi-asserted-by":"crossref","first-page":"262","DOI":"10.3109\/02652048.2011.646330","article-title":"Trigger release liposome systems: local and remote controlled delivery?","volume":"29","author":"Bibi","year":"2012","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ijpx.2025.100478_bb0180","doi-asserted-by":"crossref","first-page":"617","DOI":"10.1016\/j.jconrel.2024.07.021","article-title":"Rational formulation and industrial manufacturing of lipid-based complex injectables: landmarks and trends","volume":"373","author":"Biscaia-Caleiras","year":"2024","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2025.100478_bb0185","series-title":"Amphotericin B Liposomal 50mg Powder for Dispersion for Infusion Vials","author":"BNF","year":"2025"},{"key":"10.1016\/j.ijpx.2025.100478_bb0190","doi-asserted-by":"crossref","first-page":"405","DOI":"10.5731\/pdajpst.2017.007849","article-title":"Application of Recombinant factor C Reagent for the Detection of Bacterial Endotoxins in Pharmaceutical Products","volume":"71","author":"Bolden","year":"2017","journal-title":"PDA J. Pharm. Sci. Technol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0195","series-title":"Sustained Release of Antiinfectives","author":"Boni","year":"2014"},{"key":"10.1016\/j.ijpx.2025.100478_bb0200","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1186\/s13756-020-00830-6","article-title":"Biofilm exacerbates antibiotic resistance: is this a current oversight in antimicrobial stewardship?","volume":"9","author":"Bowler","year":"2020","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"10.1016\/j.ijpx.2025.100478_bb0205","doi-asserted-by":"crossref","first-page":"975","DOI":"10.2147\/IJN.S68861","article-title":"Liposomes as nanomedical devices","volume":"10","author":"Bozzuto","year":"2015","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijpx.2025.100478_bb0210","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1007\/s13346-015-0220-8","article-title":"Influence of cholesterol on liposome stability and on in vitro drug release","volume":"5","author":"Briuglia","year":"2015","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ijpx.2025.100478_bb0215","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics9020012","article-title":"Liposomal formulations in clinical use: an updated review","volume":"9","author":"Bulbake","year":"2017","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2025.100478_bb0220","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1016\/j.coph.2012.06.003","article-title":"Improving known classes of antibiotics: an optimistic approach for the future","volume":"12","author":"Bush","year":"2012","journal-title":"Curr. Opin. Pharmacol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0225","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1016\/S1473-3099(10)70139-0","article-title":"Best drug treatment for multidrug-resistant and extensively drug-resistant tuberculosis","volume":"10","author":"Caminero","year":"2010","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpx.2025.100478_bb0230","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1016\/j.bcp.2016.11.019","article-title":"Antifungals","volume":"133","author":"Campoy","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0235","doi-asserted-by":"crossref","DOI":"10.3390\/molecules24101991","article-title":"Recent developments in antibacterial therapy: focus on stimuli-responsive drug-delivery systems and therapeutic nanoparticles","volume":"24","author":"Canaparo","year":"2019","journal-title":"Molecules"},{"key":"10.1016\/j.ijpx.2025.100478_bb0240","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1007\/s40121-020-00382-7","article-title":"Sixty years of Amphotericin B: an Overview of the Main Antifungal Agent used to Treat Invasive Fungal Infections","volume":"10","author":"Cavassin","year":"2021","journal-title":"Infect. Dis. Ther."},{"key":"10.1016\/j.ijpx.2025.100478_bb0245","doi-asserted-by":"crossref","first-page":"1078","DOI":"10.1002\/jps.2600840909","article-title":"Liposomal entrapment of suramin (II): Interaction of suramin with phospholipids of various chain lengths","volume":"84","author":"Chang","year":"1995","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2025.100478_bb0250","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1080\/21505594.2016.1257457","article-title":"New facets of antifungal therapy","volume":"8","author":"Chang","year":"2017","journal-title":"Virulence"},{"key":"10.1016\/j.ijpx.2025.100478_bb0255","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1016\/j.jconrel.2009.10.024","article-title":"An overview of liposome lyophilization and its future potential","volume":"142","author":"Chen","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2025.100478_bb0260","article-title":"Prophylactic use amphotericin B use in patients with hematologic disorders complicated by neutropenia: a systematic review and meta-analysis","volume":"13","author":"Chen","year":"2023","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijpx.2025.100478_bb0265","doi-asserted-by":"crossref","DOI":"10.1371\/journal.ppat.1006290","article-title":"Candida auris: A rapidly emerging cause of hospital-acquired multidrug-resistant fungal infections globally","volume":"13","author":"Chowdhary","year":"2017","journal-title":"PLoS Pathog."},{"key":"10.1016\/j.ijpx.2025.100478_bb0270","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1136\/thoraxjnl-2012-202230","article-title":"Phase II studies of nebulised Arikace in CF patients with Pseudomonas aeruginosa infection","volume":"68","author":"Clancy","year":"2013","journal-title":"Thorax"},{"key":"10.1016\/j.ijpx.2025.100478_bb0275","doi-asserted-by":"crossref","first-page":"329","DOI":"10.1093\/clinids\/23.2.329","article-title":"Relevance of digestive tract colonization in the epidemiology of nosocomial infections due to multiresistant Acinetobacter baumannii","volume":"23","author":"Corbella","year":"1996","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpx.2025.100478_bb0280","doi-asserted-by":"crossref","first-page":"533","DOI":"10.1128\/AAC.44.3.533-539.2000","article-title":"Antibacterial efficacy of gentamicin encapsulated in pH-sensitive liposomes against an in vivo Salmonella enterica serovar typhimurium intracellular infection model","volume":"44","author":"Cordeiro","year":"2000","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb0285","doi-asserted-by":"crossref","first-page":"e405","DOI":"10.1016\/S1473-3099(19)30312-3","article-title":"Global guideline for the diagnosis and management of mucormycosis: an initiative of the European Confederation of Medical Mycology in cooperation with the Mycoses Study Group Education and Research Consortium","volume":"19","author":"Cornely","year":"2019","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpx.2025.100478_bb0290","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00535-2020","article-title":"Treatment of nontuberculous mycobacterial pulmonary disease: an official ATS\/ERS\/ESCMID\/IDSA clinical practice guideline","volume":"56","author":"Daley","year":"2020","journal-title":"Eur. Respir. J."},{"key":"10.1016\/j.ijpx.2025.100478_bb0295","doi-asserted-by":"crossref","first-page":"280","DOI":"10.1038\/s41579-022-00820-y","article-title":"Molecular mechanisms of antibiotic resistance revisited","volume":"21","author":"Darby","year":"2023","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0300","doi-asserted-by":"crossref","DOI":"10.1128\/CMR.00181-19","article-title":"Antimicrobial resistance in ESKAPE pathogens","volume":"33","author":"De Oliveira","year":"2020","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ijpx.2025.100478_bb0305","doi-asserted-by":"crossref","first-page":"562","DOI":"10.1016\/j.ijantimicag.2017.11.009","article-title":"Higher versus standard amikacin single dose in emergency department patients with severe sepsis and septic shock: a randomised controlled trial","volume":"51","author":"De Winter","year":"2018","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ijpx.2025.100478_bb0310","first-page":"10","article-title":"The antifungal mechanism of Amphotericin B elucidated in ergosterol and cholesterol-containing membranes using neutron reflectometry","author":"Delhom","year":"2020","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.ijpx.2025.100478_bb0315","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1159\/000014208","article-title":"Treatment of Gram-negative bacterial meningitis in term neonates with third generation Cephalosporins plus Amikacin","volume":"77","author":"Dellagrammaticas","year":"2000","journal-title":"Biol. Neonate"},{"key":"10.1016\/j.ijpx.2025.100478_bb0320","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120271","article-title":"Sterilization methods of liposomes: Drawbacks of conventional methods and perspectives","volume":"597","author":"Delma","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb0325","doi-asserted-by":"crossref","first-page":"e428","DOI":"10.1016\/S1473-3099(23)00692-8","article-title":"Global incidence and mortality of severe fungal disease","volume":"24","author":"Denning","year":"2024","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpx.2025.100478_bb0330","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1664","article-title":"Intrinsic stimuli-responsive nanocarriers for smart drug delivery of antibacterial agents\u2014an in-depth review of the last two decades","volume":"13","author":"Devnarain","year":"2021","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0335","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/BF01710685","article-title":"The effect of liposomal cefoperazone against Pseudomonas aeruginosa in a granulocytopenic mouse model of acute lung infection","volume":"20","author":"Di Rocco","year":"1992","journal-title":"Infection"},{"key":"10.1016\/j.ijpx.2025.100478_bb0340","doi-asserted-by":"crossref","first-page":"482","DOI":"10.1007\/s12598-021-01802-4","article-title":"Stimuli-responsive nanocarriers for bacterial biofilm treatment","volume":"41","author":"Ding","year":"2022","journal-title":"Rare Metals"},{"key":"10.1016\/j.ijpx.2025.100478_bb0345","doi-asserted-by":"crossref","DOI":"10.1126\/sciadv.abd5230","article-title":"Polarization-sensitive stimulated Raman scattering imaging resolves amphotericin B orientation in Candida membrane","volume":"7","author":"Dong","year":"2021","journal-title":"Sci. Adv."},{"key":"10.1016\/j.ijpx.2025.100478_bb0350","doi-asserted-by":"crossref","first-page":"500","DOI":"10.1007\/s13346-021-01024-2","article-title":"Current hurdles to the translation of nanomedicines from bench to the clinic","volume":"12","author":"\u0110or\u0111evi\u0107","year":"2022","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ijpx.2025.100478_bb0355","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.2147\/IJN.S146195","article-title":"Nanotechnology-based drug delivery systems for control of microbial biofilms: a review","volume":"13","author":"Dos Santos Ramos","year":"2018","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijpx.2025.100478_bb0360","doi-asserted-by":"crossref","first-page":"351","DOI":"10.2165\/00003495-200767030-00003","article-title":"The epidemiology, pathogenesis and treatment of Pseudomonas aeruginosa infections","volume":"67","author":"Driscoll","year":"2007","journal-title":"Drugs"},{"key":"10.1016\/j.ijpx.2025.100478_bb0365","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.ijpharm.2009.11.033","article-title":"Liposomes as delivery systems for antibiotics","volume":"387","author":"Drulis-Kawa","year":"2010","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb0370","doi-asserted-by":"crossref","first-page":"211","DOI":"10.1016\/j.ijpharm.2008.09.043","article-title":"The interaction between Pseudomonas aeruginosa cells and cationic PC:Chol:DOTAP liposomal vesicles versus outer-membrane structure and envelope properties of bacterial cell","volume":"367","author":"Drulis-Kawa","year":"2009","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb0375","doi-asserted-by":"crossref","first-page":"3271","DOI":"10.1158\/0008-5472.CAN-05-4007","article-title":"Development of a highly active nanoliposomal irinotecan using a novel intraliposomal stabilization strategy","volume":"66","author":"Drummond","year":"2006","journal-title":"Cancer Res."},{"key":"10.1016\/j.ijpx.2025.100478_bb0380","doi-asserted-by":"crossref","DOI":"10.3390\/ph13050083","article-title":"Polymyxin delivery systems: recent advances and challenges","volume":"13","author":"Dubashynskaya","year":"2020","journal-title":"Pharmaceuticals (Basel)"},{"key":"10.1016\/j.ijpx.2025.100478_bb0385","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1093\/jac\/49.suppl_1.31","article-title":"Overview of the lipid formulations of amphotericin B","volume":"49","author":"Dupont","year":"2002","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb0390","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/S0169-409X(99)00037-X","article-title":"Mechanisms and kinetics of liposome\u2013cell interactions","volume":"40","author":"D\u00fczg\u00fcne\u015f","year":"1999","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpx.2025.100478_bb0395","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1007\/s10585-019-09966-1","article-title":"The extracellular matrix in tumor progression and metastasis","volume":"36","author":"Eble","year":"2019","journal-title":"Clin. Exp. Metastasis"},{"key":"10.1016\/j.ijpx.2025.100478_bb0400","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.2217\/fmb.15.117","article-title":"Management of Pseudomonas aeruginosa infection in cystic fibrosis patients using inhaled antibiotics with a focus on nebulized liposomal amikacin","volume":"10","author":"Ehsan","year":"2015","journal-title":"Future Microbiol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0405","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics12020142","article-title":"Nanomedicine fight against antibacterial resistance: an overview of the recent pharmaceutical innovations","volume":"12","author":"Eleraky","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2025.100478_bb0410","doi-asserted-by":"crossref","first-page":"1254","DOI":"10.1086\/529198","article-title":"Acinetobacter baumannii: epidemiology, antimicrobial resistance, and treatment options","volume":"46","author":"Eliopoulos","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpx.2025.100478_bb0415","doi-asserted-by":"crossref","first-page":"199","DOI":"10.1097\/00000542-200207000-00028","article-title":"Influence of lung aeration on pulmonary concentrations of nebulized and intravenous amikacin in ventilated piglets with severe bronchopneumonia","volume":"97","author":"Elman","year":"2002","journal-title":"J. Am. Soc. Anesthesiol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0420","series-title":"European Medicines Agency (EMA), Committee for Medicinal Products for Human Use (CHMP), London, UK","article-title":"Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product","author":"EMA","year":"2011"},{"key":"10.1016\/j.ijpx.2025.100478_bb0425","series-title":"EMA\/CHMP\/806058\/2009\/Rev. 02 European Medicines Agency, Amsterdam, the Netherlands","article-title":"Reflection paper on the data requirements for intravenous liposomal products developed with reference to an innovator liposomal product","author":"EMA","year":"2013"},{"key":"10.1016\/j.ijpx.2025.100478_bb0430","series-title":"Withdrawal Assessment Report: Arikayce (Amikacin). European Medicines Agency (EMA); Committee for Medicinal Products for Human Use (CHMP), London, UK","author":"EMA","year":"2016"},{"key":"10.1016\/j.ijpx.2025.100478_bb0435","series-title":"European Medicines Agency (EMA); Committee for Medicinal Products for Human Use (CHMP); Committee for Medicinal Products for Veterinary Use (CVMP), Amsterdam, The Netherlands","article-title":"Guideline on the sterilisation of the medicinal product, active substance, excipient and primary container","author":"EMA","year":"2019"},{"key":"10.1016\/j.ijpx.2025.100478_bb0440","series-title":"Arikayce liposomal 590 mg nebuliser dispersion","author":"EMA","year":"2020"},{"key":"10.1016\/j.ijpx.2025.100478_bb0445","series-title":"Arikayce Liposomal: EPAR - Public Assessment Report","author":"EMA","year":"2020"},{"key":"10.1016\/j.ijpx.2025.100478_bb0450","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1111\/j.1439-0507.2009.01805.x","article-title":"Continuous infusion of amphotericin B deoxycholate: an innovative, low-cost strategy in antifungal treatment","volume":"54","author":"Falci","year":"2011","journal-title":"Mycoses"},{"key":"10.1016\/j.ijpx.2025.100478_bb0455","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1111\/myc.12283","article-title":"Comparison of nephrotoxicity associated to different lipid formulations of amphotericin B: a real-life study","volume":"58","author":"Falci","year":"2015","journal-title":"Mycoses"},{"key":"10.1016\/j.ijpx.2025.100478_bb0460","doi-asserted-by":"crossref","first-page":"8121","DOI":"10.2147\/IJN.S335804","article-title":"Facile biofilm penetration of cationic liposomes loaded with DNase I\/Proteinase K to eradicate cutibacterium acnes for treating cutaneous and catheter infections","volume":"16","author":"Fang","year":"2021","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijpx.2025.100478_bb0465","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/s10123-021-00219-4","article-title":"Stress impact of liposomes loaded with ciprofloxacin on the expression level of MepA and NorB efflux pumps of methicillin-resistant Staphylococcus aureus","volume":"25","author":"Faraag","year":"2022","journal-title":"Int. Microbiol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0470","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1016\/j.colsurfb.2018.05.028","article-title":"Polymeric nanoparticles as a platform for permeability enhancement of class III drug amikacin","volume":"169","author":"Fatima","year":"2018","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.ijpx.2025.100478_bb0475","doi-asserted-by":"crossref","first-page":"29","DOI":"10.3390\/pharmaceutics12010029","article-title":"Lipid systems for the delivery of Amphotericin B in antifungal therapy","volume":"12","author":"Faustino","year":"2020","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2025.100478_bb0480","series-title":"Approval Package for Onivyde","author":"FDA","year":"2015"},{"key":"10.1016\/j.ijpx.2025.100478_bb0485","series-title":"Arikayce\u00ae (amikacin liposome inhalation suspension): US prescribing information","author":"FDA","year":"2018"},{"key":"10.1016\/j.ijpx.2025.100478_bb0490","series-title":"Liposome Drug Products Chemistry, Manufacturing, and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER)","author":"FDA","year":"2018"},{"key":"10.1016\/j.ijpx.2025.100478_bb0495","series-title":"Draft Guidance on Amphotericin B Liposome Injection: Bioequivalence Recommendations for Specific Products","author":"FDA","year":"2020"},{"key":"10.1016\/j.ijpx.2025.100478_bb0500","series-title":"Draft Guidance on Amphotericin B","author":"FDA","year":"2020"},{"key":"10.1016\/j.ijpx.2025.100478_bb0505","doi-asserted-by":"crossref","first-page":"139","DOI":"10.1016\/j.ijpharm.2017.04.013","article-title":"Unmet clinical needs in the treatment of systemic fungal infections: the role of amphotericin B and drug targeting","volume":"525","author":"Fern\u00e1ndez-Garc\u00eda","year":"2017","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb0510","doi-asserted-by":"crossref","first-page":"72","DOI":"10.1007\/s13346-020-00791-8","article-title":"Lipid-based nanosystems for targeting bone implant-associated infections: current approaches and future endeavors","volume":"11","author":"Ferreira","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ijpx.2025.100478_bb0515","doi-asserted-by":"crossref","DOI":"10.3390\/molecules26072047","article-title":"Liposomes as antibiotic delivery systems: a promising nanotechnological strategy against antimicrobial resistance","volume":"26","author":"Ferreira","year":"2021","journal-title":"Molecules"},{"key":"10.1016\/j.ijpx.2025.100478_bb0520","doi-asserted-by":"crossref","first-page":"1775","DOI":"10.1023\/A:1011925132473","article-title":"Altered tissue distribution and elimination of Amikacin Encapsulated in Unilamellar, Low-clearance Liposomes (MiKasome\u00ae)","volume":"15","author":"Fielding","year":"1998","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpx.2025.100478_bb0525","series-title":"Long Circulating Liposomes: Old Drugs, New Therapeutics","first-page":"213","article-title":"Clinical and Preclinical Studies with Low-Clearance Liposomal Amikacin (MiKasome\u00ae)","author":"Fielding","year":"1998"},{"key":"10.1016\/j.ijpx.2025.100478_bb0530","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1128\/AAC.43.3.503","article-title":"Pharmacokinetics and urinary excretion of amikacin in low-clearance unilamellar liposomes after a single or repeated intravenous administration in the rhesus monkey","volume":"43","author":"Fielding","year":"1999","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb0535","doi-asserted-by":"crossref","first-page":"623","DOI":"10.1038\/nrmicro2415","article-title":"The biofilm matrix","volume":"8","author":"Flemming","year":"2010","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0540","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1007\/s40800-016-0028-6","article-title":"Confusion between two Amphotericin B formulations leading to a paediatric rehospitalisation","volume":"3","author":"Fleury","year":"2016","journal-title":"Drug Saf. Case Rep."},{"key":"10.1016\/j.ijpx.2025.100478_bb0545","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.jconrel.2014.03.055","article-title":"Lipid and polymer nanoparticles for drug delivery to bacterial biofilms","volume":"190","author":"Forier","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2025.100478_bb0550","doi-asserted-by":"crossref","first-page":"419","DOI":"10.2165\/00003088-200342050-00002","article-title":"Pharmacokinetics of Pegylated Liposomal Doxorubicin","volume":"42","author":"Gabizon","year":"2003","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ijpx.2025.100478_bb0555","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0168862","article-title":"About the sterilization of chitosan hydrogel nanoparticles","volume":"11","author":"Galante","year":"2016","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpx.2025.100478_bb0560","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1039\/D1BM01537K","article-title":"Nanoemulsion delivery systems for enhanced efficacy of antimicrobials and essential oils","volume":"10","author":"Garcia","year":"2022","journal-title":"Biomater. Sci."},{"key":"10.1016\/j.ijpx.2025.100478_bb0565","doi-asserted-by":"crossref","first-page":"1892","DOI":"10.1002\/cncr.24204","article-title":"Efficacy and safety of liposomal cytarabine in lymphoma patients with central nervous system involvement from lymphoma","volume":"115","author":"Garcia-Marco","year":"2009","journal-title":"Cancer"},{"key":"10.1016\/j.ijpx.2025.100478_bb0570","doi-asserted-by":"crossref","first-page":"35442","DOI":"10.1021\/acsomega.3c04893","article-title":"Liposome-based antibacterial delivery: an emergent approach to combat bacterial infections","volume":"8","author":"Ghosh","year":"2023","journal-title":"ACS Omega"},{"key":"10.1016\/j.ijpx.2025.100478_bb0575","doi-asserted-by":"crossref","first-page":"98S","DOI":"10.1046\/j.1365-2672.92.5s1.5.x","article-title":"Biofilms in vitro and in vivo: do singular mechanisms imply cross-resistance?","volume":"92","author":"Gilbert","year":"2002","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0580","series-title":"Amphotericin B Gilead Liposomal 50 mg Powder for Dispersion for Infusion - Summary of Product Characteristics. Medicines and Healthcare products Regulatory Agency (MHRA) \/ EMC","author":"Gilead","year":"2024"},{"key":"10.1016\/j.ijpx.2025.100478_bb0585","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1200\/JCO.1996.14.8.2353","article-title":"Randomized phase III trial of liposomal daunorubicin versus doxorubicin, bleomycin, and vincristine in AIDS-related Kaposi\u2019s sarcoma","volume":"14","author":"Gill","year":"1996","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0590","doi-asserted-by":"crossref","first-page":"3110","DOI":"10.1200\/JCO.1999.17.10.3110","article-title":"Randomized trial of a slow-release versus a standard formulation of cytarabine for the intrathecal treatment of lymphomatous meningitis","volume":"17","author":"Glantz","year":"1999","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0595","doi-asserted-by":"crossref","first-page":"173","DOI":"10.1111\/myc.12294","article-title":"Nebulised liposomal amphotericin B for Aspergillus lung diseases: case series and literature review","volume":"58","author":"Godet","year":"2015","journal-title":"Mycoses"},{"key":"10.1016\/j.ijpx.2025.100478_bb0600","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/j.chom.2014.02.003","article-title":"Host immune response to infection and cancer: unexpected commonalities","volume":"15","author":"Goldszmid","year":"2014","journal-title":"Cell Host Microbe"},{"key":"10.1016\/j.ijpx.2025.100478_bb0605","doi-asserted-by":"crossref","first-page":"896","DOI":"10.1021\/acsinfecdis.9b00357","article-title":"Liposomes for antibiotic encapsulation and delivery","volume":"6","author":"Gomez","year":"2020","journal-title":"ACS Infect. Diseas."},{"key":"10.1016\/j.ijpx.2025.100478_bb0610","doi-asserted-by":"crossref","first-page":"733","DOI":"10.1007\/s10517-006-0069-4","article-title":"Fusion and endocytosis of anionic liposomes with Ehrlich ascitic carcinoma cells","volume":"140","author":"Goryacheva","year":"2005","journal-title":"Bull. Exp. Biol. Med."},{"key":"10.1016\/j.ijpx.2025.100478_bb0615","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1017\/S026646231800034X","article-title":"Comparative effectiveness and safety between Amphotericin B lipid-formulations: a systematic review","volume":"34","author":"Grazziotin","year":"2018","journal-title":"Int. J. Technol. Assess. Health Care"},{"key":"10.1016\/j.ijpx.2025.100478_bb0620","doi-asserted-by":"crossref","first-page":"4202","DOI":"10.1021\/acs.molpharmaceut.8b00572","article-title":"Mechanism of binding of antifungal antibiotic Amphotericin B to lipid membranes: an insight from combined single-membrane imaging, microspectroscopy, and molecular dynamics","volume":"15","author":"Grela","year":"2018","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb0625","doi-asserted-by":"crossref","first-page":"1559","DOI":"10.1164\/rccm.201807-1318OC","article-title":"Amikacin liposome inhalation suspension for treatment-refractory lung disease caused by mycobacterium avium complex (CONVERT). A prospective, open-label, randomized study","volume":"198","author":"Griffith","year":"2018","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ijpx.2025.100478_bb0630","doi-asserted-by":"crossref","first-page":"52","DOI":"10.53941\/ijddp.0201009","article-title":"Recent clinical successes in liposomal nanomedicines","volume":"2","author":"Gu","year":"2023","journal-title":"Intern. J. Drug Discov. Pharmacol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0635","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2021.120571","article-title":"Design of liposomes as drug delivery system for therapeutic applications","volume":"601","author":"Guimar\u00e3es","year":"2021","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb0640","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1080\/10717540600814402","article-title":"Pharmacokinetic consequences of pegylation","volume":"13","author":"Hamidi","year":"2006","journal-title":"Drug Deliv."},{"key":"10.1016\/j.ijpx.2025.100478_bb0645","doi-asserted-by":"crossref","first-page":"919","DOI":"10.1007\/s40265-013-0069-4","article-title":"Amphotericin B formulations: a comparative review of efficacy and toxicity","volume":"73","author":"Hamill","year":"2013","journal-title":"Drugs"},{"key":"10.1016\/j.ijpx.2025.100478_bb0650","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1146\/annurev.micro.56.012302.160310","article-title":"Function of pseudomonas porins in uptake and efflux","volume":"56","author":"Hancock","year":"2002","journal-title":"Ann. Rev. Microbiol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0655","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3816\/CGC.2002.n.005","article-title":"Liposomal doxorubicin for the treatment of hormone-refractory prostate cancer","volume":"1","author":"Harris","year":"2002","journal-title":"Clin. Prostate Cancer"},{"key":"10.1016\/j.ijpx.2025.100478_bb0660","doi-asserted-by":"crossref","first-page":"45","DOI":"10.1097\/CCM.0000000000002695","article-title":"Nebulized versus IV Amikacin as adjunctive antibiotic for hospital and ventilator-acquired pneumonia postcardiac surgeries: a randomized controlled trial","volume":"46","author":"Hassan","year":"2018","journal-title":"Crit. Care Med."},{"key":"10.1016\/j.ijpx.2025.100478_bb0665","doi-asserted-by":"crossref","first-page":"1275","DOI":"10.1128\/AAC.41.6.1275","article-title":"Pharmacokinetics of liposomal amphotericin B (Ambisome) in critically ill patients","volume":"41","author":"Heinemann","year":"1997","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb0670","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/S0169-409X(96)00496-6","article-title":"Supramolecular lipidic drug delivery systems: from laboratory to clinic A review of the recently introduced commercial liposomal and lipid-based formulations of amphotericin B","volume":"24","author":"Hillery","year":"1997","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpx.2025.100478_bb0675","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1016\/S1473-3099(01)00091-3","article-title":"Vancomycin-resistant Staphylococcus aureus: a new model of antibiotic resistance","volume":"1","author":"Hiramatsu","year":"2001","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpx.2025.100478_bb0680","doi-asserted-by":"crossref","first-page":"885","DOI":"10.1111\/myc.12836","article-title":"Global guidelines and initiatives from the European Confederation of Medical Mycology to improve patient care and research worldwide: new leadership is about working together","volume":"61","author":"Hoenigl","year":"2018","journal-title":"Mycoses"},{"key":"10.1016\/j.ijpx.2025.100478_bb0685","doi-asserted-by":"crossref","first-page":"1088","DOI":"10.1002\/ejlt.201400219","article-title":"The use of natural and synthetic phospholipids as pharmaceutical excipients","volume":"116","author":"van Hoogevest","year":"2014","journal-title":"Eur. J. Lipid Sci. Technol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0690","series-title":"Liposome-Based Drug Delivery Systems","first-page":"3","article-title":"Liposomes in drug delivery: Status and advances","author":"Hu","year":"2021"},{"key":"10.1016\/j.ijpx.2025.100478_bb0695","doi-asserted-by":"crossref","first-page":"214","DOI":"10.1016\/j.biomaterials.2010.08.076","article-title":"Eradication of drug resistant Staphylococcus aureus by liposomal oleic acids","volume":"32","author":"Huang","year":"2011","journal-title":"Biomaterials"},{"key":"10.1016\/j.ijpx.2025.100478_bb0700","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1208\/s12249-024-02753-6","article-title":"Liposomal formulation reduces transport and cell uptake of colistin in human lung epithelial Calu-3 Cell and 3D human lung primary tissue models","volume":"25","author":"Huang","year":"2024","journal-title":"AAPS PharmSciTech"},{"key":"10.1016\/j.ijpx.2025.100478_bb0705","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1007\/s00402-008-0782-8","article-title":"Treatment of osteomyelitis by liposomal gentamicin-impregnated calcium sulfate","volume":"129","author":"Hui","year":"2009","journal-title":"Arch. Orthop. Trauma Surg."},{"key":"10.1016\/j.ijpx.2025.100478_bb0710","doi-asserted-by":"crossref","first-page":"21","DOI":"10.2147\/IJN.S1253","article-title":"Tumor targeting using liposomal antineoplastic drugs","volume":"3","author":"Huwyler","year":"2008","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijpx.2025.100478_bb0715","doi-asserted-by":"crossref","first-page":"6987","DOI":"10.1007\/s11033-021-06690-6","article-title":"Multidrug-resistant Acinetobacter baumannii as an emerging concern in hospitals","volume":"48","author":"Ibrahim","year":"2021","journal-title":"Mol. Biol. Rep."},{"key":"10.1016\/j.ijpx.2025.100478_bb0720","series-title":"ICH Topic Q3B (R2) Impurities in New Drug Products International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH)","author":"ICH","year":"2006"},{"key":"10.1016\/j.ijpx.2025.100478_bb0725","series-title":"International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human use (ICH), Geneva, Switzerland","article-title":"ICH guideline Q3C (R9) on impurities: Guideline for residual solvents \u2013 Step 5","author":"ICH","year":"2024"},{"key":"10.1016\/j.ijpx.2025.100478_bb0730","doi-asserted-by":"crossref","first-page":"2221","DOI":"10.1016\/S0140-6736(22)02185-7","article-title":"Global mortality associated with 33 bacterial pathogens in 2019: a systematic analysis for the Global Burden of Disease Study 2019","volume":"400","author":"Ikuta","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijpx.2025.100478_bb0735","doi-asserted-by":"crossref","DOI":"10.3390\/nano10020190","article-title":"Immunological and toxicological considerations for the design of liposomes","volume":"10","author":"Inglut","year":"2020","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.ijpx.2025.100478_bb0740","doi-asserted-by":"crossref","DOI":"10.3390\/jpm12121964","article-title":"Enhanced permeability and retention effect as a ubiquitous and epoch-making phenomenon for the selective drug targeting of solid tumors","volume":"12","author":"Islam","year":"2022","journal-title":"J. Pers. Med."},{"key":"10.1016\/j.ijpx.2025.100478_bb0745","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1007\/s42770-023-01189-7","article-title":"The use of combination therapy for the improvement of colistin activity against bacterial biofilm","volume":"55","author":"Jalil","year":"2024","journal-title":"Braz. J. Microbiol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0750","doi-asserted-by":"crossref","first-page":"279","DOI":"10.2165\/00003088-199223040-00004","article-title":"Liposomal and lipid formulations of Amphotericin B","volume":"23","author":"Janknegt","year":"1992","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ijpx.2025.100478_bb0755","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1056\/NEJMoa2111904","article-title":"Single-Dose Liposomal Amphotericin B Treatment for Cryptococcal Meningitis","volume":"386","author":"Jarvis","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpx.2025.100478_bb0760","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1016\/j.addr.2020.07.016","article-title":"Opportunities and challenges in commercial pharmaceutical liposome applications","volume":"154-155","author":"Jensen","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpx.2025.100478_bb0765","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1211\/0022357055092","article-title":"Kanamycin incorporation in lipid vesicles prepared by ethanol injection designed for tuberculosis treatment","volume":"57","author":"Justo","year":"2005","journal-title":"J. Pharm. Pharmacol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0770","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1038\/s41578-021-00362-4","article-title":"Biomaterial-based antimicrobial therapies for the treatment of bacterial infections","volume":"7","author":"Kalelkar","year":"2022","journal-title":"Nat. Rev. Mater."},{"key":"10.1016\/j.ijpx.2025.100478_bb0775","doi-asserted-by":"crossref","DOI":"10.3390\/microorganisms12030516","article-title":"A Study on the application of recombinant factor C (rFC) assay using biopharmaceuticals","volume":"12","author":"Kang","year":"2024","journal-title":"Microorganisms"},{"key":"10.1016\/j.ijpx.2025.100478_bb0780","doi-asserted-by":"crossref","first-page":"632","DOI":"10.1208\/s12248-017-0049-9","article-title":"Liposomal drug product development and quality: current us experience and perspective","volume":"19","author":"Kapoor","year":"2017","journal-title":"AAPS J."},{"key":"10.1016\/j.ijpx.2025.100478_bb0785","doi-asserted-by":"crossref","DOI":"10.1155\/2011\/727241","article-title":"Targeted liposomal drug delivery to monocytes and macrophages","volume":"2011","author":"Kelly","year":"2011","journal-title":"J. Drug Deliv."},{"key":"10.1016\/j.ijpx.2025.100478_bb0790","doi-asserted-by":"crossref","first-page":"989","DOI":"10.3109\/03639045.2014.920025","article-title":"Investigation of the antibacterial activity and efflux pump inhibitory effect of co-loaded piperine and gentamicin nanoliposomes in methicillin-resistant Staphylococcus aureus","volume":"41","author":"Khameneh","year":"2015","journal-title":"Drug Dev. Ind. Pharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb0795","doi-asserted-by":"crossref","first-page":"2287","DOI":"10.2147\/DDDT.S146111","article-title":"The use of Amikacin liposome inhalation suspension (Arikayce) in the treatment of refractory nontuberculous mycobacterial lung disease in adults","volume":"14","author":"Khan","year":"2020","journal-title":"Drug Des. Devel. Ther."},{"key":"10.1016\/j.ijpx.2025.100478_bb0800","doi-asserted-by":"crossref","first-page":"416","DOI":"10.1016\/j.xphs.2022.11.025","article-title":"Drug stability and minimized acid-\/drug-catalyzed phospholipid degradation in liposomal irinotecan","volume":"112","author":"Kirpotin","year":"2023","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2025.100478_bb0805","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1016\/j.ijantimicag.2006.03.013","article-title":"What is the current and future status of conventional amphotericin B?","volume":"27","author":"Kleinberg","year":"2006","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ijpx.2025.100478_bb0810","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jconrel.2014.04.047","article-title":"Designer lipids for drug delivery: from heads to tails","volume":"190","author":"Kohli","year":"2014","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2025.100478_bb0815","article-title":"Different liposomal amphotericin B formulations for visceral leishmaniasis–Author\u2019s reply","volume":"2","author":"Kshirsagar","year":"2014","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.ijpx.2025.100478_bb0820","doi-asserted-by":"crossref","DOI":"10.1016\/j.nxnano.2025.100228","article-title":"Solid lipid nanoparticles based drug delivery for major infectious diseases: a narrative review","volume":"8","author":"Kumar","year":"2025","journal-title":"Next Nanotechnol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0825","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-024-68647-6","article-title":"Maleimide conjugated PEGylated liposomal antibiotic to combat multi-drug resistant Escherichia coli and Klebsiella pneumoniae with enhanced wound healing potential","volume":"14","author":"Ladva","year":"2024","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijpx.2025.100478_bb0830","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1002\/jbm.a.37501","article-title":"Antifungal liposomes: Lipid saturation and cholesterol concentration impact interaction with fungal and mammalian cells","volume":"111","author":"LaMastro","year":"2023","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.ijpx.2025.100478_bb0835","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.riam.2009.06.003","article-title":"Amphotericin B: side effects and toxicity","volume":"26","author":"Laniado-Labor\u00edn","year":"2009","journal-title":"Rev. Iberoam. Micol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0840","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113851","article-title":"Liposome composition in drug delivery design, synthesis, characterization, and clinical application","volume":"176","author":"Large","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpx.2025.100478_bb0845","doi-asserted-by":"crossref","first-page":"347","DOI":"10.1016\/S0168-3659(01)00402-3","article-title":"Microscopic localization of PEG-liposomes in a rat model of focal infection","volume":"75","author":"Laverman","year":"2001","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2025.100478_bb0850","doi-asserted-by":"crossref","first-page":"e1845","DOI":"10.1016\/S2214-109X(22)00450-8","article-title":"Cost-effectiveness of single, high-dose, liposomal amphotericin regimen for HIV-associated cryptococcal meningitis in five countries in sub-Saharan Africa: an economic analysis of the AMBITION-cm trial","volume":"10","author":"Lawrence","year":"2022","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.ijpx.2025.100478_bb0855","doi-asserted-by":"crossref","first-page":"e1552","DOI":"10.1016\/S2214-109X(24)00225-0","article-title":"Paving the way for affordable and equitable liposomal amphotericin B access worldwide","volume":"12","author":"Lee","year":"2024","journal-title":"Lancet Glob. Health"},{"key":"10.1016\/j.ijpx.2025.100478_bb0860","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1080\/08982100500364131","article-title":"The effect of cholesterol in the liposome bilayer on the stabilization of incorporated retinol","volume":"15","author":"Lee","year":"2005","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ijpx.2025.100478_bb0865","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1021\/acs.chemrev.0c00199","article-title":"Antifungal drug resistance: molecular mechanisms in Candida albicans and beyond","volume":"121","author":"Lee","year":"2020","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ijpx.2025.100478_bb0870","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1111\/j.1468-3083.2009.03100.x","article-title":"Liposomes in dermatology today","volume":"23","author":"de Leeuw","year":"2009","journal-title":"J. Eur. Acad. Dermatol. Venereol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0875","doi-asserted-by":"crossref","DOI":"10.1128\/AAC.00090-17","article-title":"Experimental models of short courses of liposomal amphotericin b for induction therapy for cryptococcal meningitis","volume":"61","author":"Lestner","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb0880","doi-asserted-by":"crossref","first-page":"972","DOI":"10.1038\/s41594-021-00685-4","article-title":"Fungicidal amphotericin B sponges are assemblies of staggered asymmetric homodimers encasing large void volumes","volume":"28","author":"Lewandowska","year":"2021","journal-title":"Nat. Struct. Mol. Biol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0885","doi-asserted-by":"crossref","first-page":"87","DOI":"10.1016\/j.bcp.2016.11.002","article-title":"New approaches to antimicrobial discovery","volume":"134","author":"Lewis","year":"2017","journal-title":"Biochem. Pharmacol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0890","first-page":"12","article-title":"Current and emerging inhaled antibiotics for chronic pulmonary Pseudomonas aeruginosa and Staphylococcus aureus infections in cystic fibrosis","author":"Li","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijpx.2025.100478_bb0895","first-page":"81","article-title":"A review on phospholipids and their main applications in drug delivery systems","volume":"10","author":"Li","year":"2015","journal-title":"Asian J. Pharmaceut. Sci."},{"key":"10.1016\/j.ijpx.2025.100478_bb0900","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1016\/j.jconrel.2010.01.006","article-title":"Triggered content release from optimized stealth thermosensitive liposomes using mild hyperthermia","volume":"143","author":"Li","year":"2010","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2025.100478_bb0905","doi-asserted-by":"crossref","first-page":"640","DOI":"10.1016\/j.ejmech.2019.01.007","article-title":"Composition design and medical application of liposomes","volume":"164","author":"Li","year":"2019","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ijpx.2025.100478_bb0910","doi-asserted-by":"crossref","first-page":"436","DOI":"10.1080\/10837450.2016.1228666","article-title":"Electrostatically entrapped colistin liposomes for the treatment of Pseudomonas aeruginosa infection","volume":"22","author":"Li","year":"2017","journal-title":"Pharm. Dev. Technol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0915","doi-asserted-by":"crossref","first-page":"245","DOI":"10.1089\/jamp.2008.0686","article-title":"Characterization of nebulized liposomal amikacin (Arikace) as a function of droplet size","volume":"21","author":"Li","year":"2008","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ijpx.2025.100478_bb0920","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/j.jconrel.2012.06.002","article-title":"Improvement of drug safety by the use of lipid-based nanocarriers","volume":"163","author":"Lim","year":"2012","journal-title":"J. Control. Release"},{"key":"10.1016\/j.ijpx.2025.100478_bb0925","series-title":"Liposome-Based Drug Delivery Systems","first-page":"123","article-title":"Quality Evaluation of Drug-Loaded Liposomes","author":"Lin","year":"2021"},{"key":"10.1016\/j.ijpx.2025.100478_bb0930","doi-asserted-by":"crossref","first-page":"200","DOI":"10.1126\/science.aay3041","article-title":"Effect of tolerance on the evolution of antibiotic resistance under drug combinations","volume":"367","author":"Liu","year":"2020","journal-title":"Science"},{"key":"10.1016\/j.ijpx.2025.100478_bb0935","article-title":"A review of liposomes as a drug delivery system: current status of approved products, regulatory environments, and future perspectives","volume":"27","author":"Liu","year":"2022","journal-title":"Molecules"},{"key":"10.1016\/j.ijpx.2025.100478_bb0940","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1039\/C7CS00807D","article-title":"Nanotechnology-based antimicrobials and delivery systems for biofilm-infection control","volume":"48","author":"Liu","year":"2019","journal-title":"Chem. Soc. Rev."},{"key":"10.1016\/j.ijpx.2025.100478_bb0945","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.ejpb.2020.09.008","article-title":"Analytical method development and comparability study for AmBisome\u00ae and generic Amphotericin B liposomal products","volume":"157","author":"Liu","year":"2020","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb0950","doi-asserted-by":"crossref","first-page":"564","DOI":"10.1007\/s12274-020-2655-6","article-title":"The enhanced permeability and retention effect based nanomedicine at the site of injury","volume":"13","author":"Liu","year":"2020","journal-title":"Nano Res."},{"key":"10.1016\/j.ijpx.2025.100478_bb0955","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1093\/cid\/ciw691","article-title":"Simultaneous emergence of multidrug-resistant Candida auris on 3 continents confirmed by whole-genome sequencing and epidemiological analyses","volume":"64","author":"Lockhart","year":"2017","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpx.2025.100478_bb0960","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics14030543","article-title":"Methods of liposomes preparation: formation and control factors of versatile nanocarriers for biomedical and nanomedicine application","volume":"14","author":"Lombardo","year":"2022","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2025.100478_bb0965","doi-asserted-by":"crossref","DOI":"10.3390\/nano6070125","article-title":"Soft interaction in liposome nanocarriers for therapeutic drug delivery","volume":"6","author":"Lombardo","year":"2016","journal-title":"Nanomaterials (Basel)"},{"key":"10.1016\/j.ijpx.2025.100478_bb0970","doi-asserted-by":"crossref","first-page":"547","DOI":"10.1002\/aocs.12907","article-title":"Liposomes as sustainable delivery systems in food, cosmetic, and pharmaceutical applications","volume":"102","author":"Luo","year":"2025","journal-title":"J. Am. Oil Chem. Soc."},{"key":"10.1016\/j.ijpx.2025.100478_bb0975","doi-asserted-by":"crossref","first-page":"2511","DOI":"10.1128\/AAC.42.10.2511","article-title":"Intracellular delivery and antibacterial activity of gentamicin encapsulated in pH-sensitive liposomes","volume":"42","author":"Lutwyche","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb0980","first-page":"388","article-title":"Methods of endotoxin removal from biological preparations: a review","volume":"10","author":"Magalh\u00e3es","year":"2007","journal-title":"J. Pharm. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2025.100478_bb0985","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1016\/S0966-842X(00)01913-2","article-title":"Mechanisms of biofilm resistance to antimicrobial agents","volume":"9","author":"Mah","year":"2001","journal-title":"Trends Microbiol."},{"key":"10.1016\/j.ijpx.2025.100478_bb0990","doi-asserted-by":"crossref","DOI":"10.1016\/j.supflu.2020.104984","article-title":"Sustainable technologies for liposome preparation","volume":"165","author":"Maja","year":"2020","journal-title":"J. Supercrit. Fluids"},{"key":"10.1016\/j.ijpx.2025.100478_bb0995","first-page":"12","article-title":"Liposomes-based drug delivery systems of anti-biofilm agents to combat bacterial biofilm formation","author":"Makhlouf","year":"2023","journal-title":"Antibiotics (Basel)"},{"key":"10.1016\/j.ijpx.2025.100478_bb1000","doi-asserted-by":"crossref","first-page":"6540","DOI":"10.1128\/AAC.00700-16","article-title":"Pulmonary Deposition and Elimination of Liposomal Amikacin for Inhalation and effect on Macrophage Function after Administration in Rats","volume":"60","author":"Malinin","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb1005","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2020.119478","article-title":"Vesicles as antibiotic carrier: State of art","volume":"585","author":"Marchian\u00f2","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb1010","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1093\/jac\/dkg317","article-title":"Liposomal tobramycin against pulmonary infections of Pseudomonas aeruginosa: a pharmacokinetic and efficacy study following single and multiple intratracheal administrations in rats","volume":"52","author":"Marier","year":"2003","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb1015","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2021.113829","article-title":"Nanomedicine at the crossroads \u2013 A quick guide for IVIVC","volume":"179","author":"Mast","year":"2021","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpx.2025.100478_bb1020","doi-asserted-by":"crossref","DOI":"10.1016\/j.lfs.2021.119883","article-title":"Breaking the barriers for the delivery of amikacin: challenges, strategies, and opportunities","volume":"284","author":"Maxwell","year":"2021","journal-title":"Life Sci."},{"key":"10.1016\/j.ijpx.2025.100478_bb1025","doi-asserted-by":"crossref","DOI":"10.1016\/j.colsurfb.2022.112892","article-title":"In vitro antibacterial activity and in vivo pharmacokinetics of intravenously administered Amikacin-loaded Liposomes for the management of bacterial septicaemia","volume":"220","author":"Maxwell","year":"2022","journal-title":"Colloids Surf. B: Biointerfaces"},{"key":"10.1016\/j.ijpx.2025.100478_bb1030","doi-asserted-by":"crossref","first-page":"859","DOI":"10.1093\/jac\/dkn059","article-title":"Biofilm penetration, triggered release and in vivo activity of inhaled liposomal amikacin in chronic Pseudomonas aeruginosa lung infections","volume":"61","author":"Meers","year":"2008","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb1035","doi-asserted-by":"crossref","first-page":"1901","DOI":"10.1128\/AAC.31.12.1901","article-title":"Toxicity and therapeutic effects in mice of liposome-encapsulated nystatin for systemic fungal infections","volume":"31","author":"Mehta","year":"1987","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb1040","doi-asserted-by":"crossref","DOI":"10.1098\/rstb.2015.0460","article-title":"Clinical implications of globally emerging azole resistance in Aspergillus fumigatus","volume":"371","author":"Meis","year":"2016","journal-title":"Philos. Trans. R. Soc. B"},{"key":"10.1016\/j.ijpx.2025.100478_bb1045","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1007\/s11095-015-1825-9","article-title":"Multi-functional liposomes enhancing target and antibacterial immunity for antimicrobial and anti-biofilm against methicillin-resistant Staphylococcus aureus","volume":"33","author":"Meng","year":"2016","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpx.2025.100478_bb1050","doi-asserted-by":"crossref","first-page":"286","DOI":"10.3389\/fmicb.2012.00286","article-title":"It only takes one to do many jobs: Amphotericin B as antifungal and immunomodulatory drug","volume":"3","author":"Mesa-Arango","year":"2012","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ijpx.2025.100478_bb1055","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0079220","article-title":"Transport of nanoparticles and tobramycin-loaded liposomes in Burkholderia cepacia complex biofilms","volume":"8","author":"Messiaen","year":"2013","journal-title":"PLoS One"},{"key":"10.1016\/j.ijpx.2025.100478_bb1060","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1093\/jac\/28.suppl_B.83","article-title":"Liposomal amphotericin B (AmBisome): safety data from a phase II\/III clinical trial","volume":"28","author":"Meunier","year":"1991","journal-title":"J. Antimicrob. Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb1065","doi-asserted-by":"crossref","DOI":"10.1086\/515085","article-title":"U.S. Food and Drug Administration approval of AmBisome (liposomal amphotericin B) for treatment of visceral leishmaniasis","volume":"28","author":"Meyerhoff","year":"1999","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpx.2025.100478_bb1070","series-title":"Summary of Product Characetrstics - Amphotericin B Tilomed Liposomal 50 mg Powder for Dispersion for Infusion","author":"MHRA","year":"2024"},{"key":"10.1016\/j.ijpx.2025.100478_bb1075","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1038\/s41579-024-01054-w","article-title":"ESKAPE pathogens: antimicrobial resistance, epidemiology, clinical impact and therapeutics","volume":"22","author":"Miller","year":"2024","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ijpx.2025.100478_bb1080","doi-asserted-by":"crossref","first-page":"11147","DOI":"10.1021\/acs.chemrev.5b00116","article-title":"Clinical translation of nanomedicine","volume":"115","author":"Min","year":"2015","journal-title":"Chem. Rev."},{"key":"10.1016\/j.ijpx.2025.100478_bb1085","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13104-020-05224-w","article-title":"Prevalence of multi-drug resistant (MDR) and extensively drug-resistant (XDR) phenotypes of Pseudomonas aeruginosa and Acinetobacter baumannii isolated in clinical samples from Northeast of Iran","volume":"13","author":"Mirzaei","year":"2020","journal-title":"BMC. Res. Notes"},{"key":"10.1016\/j.ijpx.2025.100478_bb1090","doi-asserted-by":"crossref","first-page":"1011","DOI":"10.1016\/S1473-3099(25)00108-2","article-title":"Estimated undertreatment of carbapenem-resistant Gram-negative bacterial infections in eight low-income and middle-income countries: a modelling study","volume":"25","author":"Mishra","year":"2025","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpx.2025.100478_bb1095","series-title":"Fungal Biofilms and Related Infections: Advances in Microbiology, Infectious Diseases and Public Health","first-page":"21","article-title":"The extracellular matrix of fungal biofilms","volume":"Vol. 3","author":"Mitchell","year":"2016"},{"key":"10.1016\/j.ijpx.2025.100478_bb1100","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1016\/S0163-7827(03)00033-X","article-title":"Stealth liposomes and long circulating nanoparticles: critical issues in pharmacokinetics, opsonization and protein-binding properties","volume":"42","author":"Moghimi","year":"2003","journal-title":"Prog. Lipid Res."},{"key":"10.1016\/j.ijpx.2025.100478_bb1105","doi-asserted-by":"crossref","DOI":"10.1098\/rsif.2014.0459","article-title":"Liposomes in tissue engineering and regenerative medicine","volume":"11","author":"Monteiro","year":"2014","journal-title":"J. R. Soc. Interface"},{"key":"10.1016\/j.ijpx.2025.100478_bb1110","series-title":"Liposomal Amphotericin B: Solving the Access Puzzle","author":"MSF","year":"2022"},{"key":"10.1016\/j.ijpx.2025.100478_bb1115","doi-asserted-by":"crossref","first-page":"629","DOI":"10.1016\/S0140-6736(21)02724-0","article-title":"Global burden of bacterial antimicrobial resistance in 2019: a systematic analysis","volume":"399","author":"Murray","year":"2022","journal-title":"Lancet"},{"key":"10.1016\/j.ijpx.2025.100478_bb1120","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1128\/AAC.27.1.137","article-title":"Enhanced liposome-mediated activity of piperacillin against staphylococci","volume":"27","author":"Nacucchio","year":"1985","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb1125","doi-asserted-by":"crossref","first-page":"303","DOI":"10.3109\/02652048809036726","article-title":"Enhanced liposome-mediated antibacterial activity of piperacillin and gentamicin against gram-negative bacilli in vitro","volume":"5","author":"Nacucchio","year":"1988","journal-title":"J. Microencapsul."},{"key":"10.1016\/j.ijpx.2025.100478_bb1130","doi-asserted-by":"crossref","first-page":"159","DOI":"10.2133\/dmpk.19.159","article-title":"Molecular aspects of renal handling of aminoglycosides and strategies for preventing the nephrotoxicity","volume":"19","author":"Nagai","year":"2004","journal-title":"Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ijpx.2025.100478_bb1135","doi-asserted-by":"crossref","first-page":"1199","DOI":"10.1016\/S0140-6736(24)01867-1","article-title":"Global burden of bacterial antimicrobial resistance 1990\u20132021: a systematic analysis with forecasts to 2050","volume":"404","author":"Naghavi","year":"2024","journal-title":"Lancet"},{"key":"10.1016\/j.ijpx.2025.100478_bb1140","series-title":"Process for the Preparation of Unilamellar Liposomal Composition","author":"Naik","year":"2017"},{"key":"10.1016\/j.ijpx.2025.100478_bb1145","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1016\/j.ijantimicag.2010.01.015","article-title":"Encapsulation in fusogenic liposomes broadens the spectrum of action of vancomycin against Gram-negative bacteria","volume":"35","author":"Nicolosi","year":"2010","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ijpx.2025.100478_bb1150","doi-asserted-by":"crossref","first-page":"155","DOI":"10.3389\/fimmu.2018.00155","article-title":"The Multirole of liposomes in therapy and prevention of infectious diseases","volume":"9","author":"Nisini","year":"2018","journal-title":"Front. Immunol."},{"key":"10.1016\/j.ijpx.2025.100478_bb1155","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2022.e09394","article-title":"Liposomes: structure, composition, types, and clinical applications","volume":"8","author":"Nsairat","year":"2022","journal-title":"Heliyon"},{"key":"10.1016\/j.ijpx.2025.100478_bb1160","doi-asserted-by":"crossref","first-page":"2104","DOI":"10.1128\/AAC.39.9.2104","article-title":"Formulation and efficacy of liposome-encapsulated antibiotics for therapy of intracellular Mycobacterium avium infection","volume":"39","author":"Oh","year":"1995","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb1165","doi-asserted-by":"crossref","first-page":"3847","DOI":"10.1128\/AAC.00872-08","article-title":"Pharmacokinetic and pharmacodynamic evaluation of liposomal amikacin for inhalation in cystic fibrosis patients with chronic pseudomonal infection","volume":"53","author":"Okusanya","year":"2009","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb1170","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1513\/AnnalsATS.201307-231OC","article-title":"Inhaled amikacin for treatment of refractory pulmonary nontuberculous mycobacterial disease","volume":"11","author":"Olivier","year":"2014","journal-title":"Ann. Am. Thorac. Soc."},{"key":"10.1016\/j.ijpx.2025.100478_bb1175","doi-asserted-by":"crossref","first-page":"814","DOI":"10.1164\/rccm.201604-0700OC","article-title":"Randomized trial of liposomal amikacin for inhalation in nontuberculous mycobacterial lung disease","volume":"195","author":"Olivier","year":"2017","journal-title":"Am. J. Respir. Crit. Care Med."},{"key":"10.1016\/j.ijpx.2025.100478_bb1180","doi-asserted-by":"crossref","first-page":"918","DOI":"10.1111\/j.1365-3156.2009.02306.x","article-title":"Cost-effectiveness projections of single and combination therapies for visceral leishmaniasis in Bihar, India","volume":"14","author":"Olliaro","year":"2009","journal-title":"Trop. Med. Int. Health"},{"key":"10.1016\/j.ijpx.2025.100478_bb1185","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1128\/AAC.00870-07","article-title":"Comparison of the physicochemical, antifungal, and toxic properties of two liposomal amphotericin B products","volume":"52","author":"Olson","year":"2008","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb1190","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1093\/mmy\/myu070","article-title":"Toxicity and efficacy differences between liposomal amphotericin B formulations in uninfected and Aspergillus fumigatus infected mice","volume":"53","author":"Olson","year":"2014","journal-title":"Med. Mycol."},{"key":"10.1016\/j.ijpx.2025.100478_bb1195","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics8040036","article-title":"Evaluation of extrusion technique for nanosizing liposomes","volume":"8","author":"Ong","year":"2016","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2025.100478_bb1200","doi-asserted-by":"crossref","first-page":"6733","DOI":"10.1073\/pnas.1015023108","article-title":"Synthesis-enabled functional group deletions reveal key underpinnings of amphotericin B ion channel and antifungal activities","volume":"108","author":"Palacios","year":"2011","journal-title":"Proc. Natl. Acad. Sci."},{"key":"10.1016\/j.ijpx.2025.100478_bb1205","series-title":"Gilead Set to Open California Production Campus for up to 500 Workers","author":"Palmer","year":"2017"},{"key":"10.1016\/j.ijpx.2025.100478_bb1210","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2024.124046","article-title":"Liposomal drug delivery strategies to eradicate bacterial biofilms: challenges, recent advances, and future perspectives","volume":"655","author":"Panthi","year":"2024","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb1215","series-title":"Systems for Treating Pulmonary Infections","author":"Perkins","year":"2017"},{"key":"10.1016\/j.ijpx.2025.100478_bb1220","doi-asserted-by":"crossref","first-page":"e383","DOI":"10.1016\/S1473-3099(17)30316-X","article-title":"The global problem of antifungal resistance: prevalence, mechanisms, and management","volume":"17","author":"Perlin","year":"2017","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpx.2025.100478_bb1225","doi-asserted-by":"crossref","DOI":"10.1016\/j.isci.2024.110349","article-title":"All hands on Dec: Treating cryptococcosis with dectin decorated liposomes loaded with antifungals","volume":"27","author":"Pham","year":"2024","journal-title":"iScience"},{"key":"10.1016\/j.ijpx.2025.100478_bb1230","series-title":"Eugia Pharma Receives USFDA Approval for Amphotericin B Liposome for Injection, 50 Mg\/Vial Single-Dose Vial","author":"Pharma","year":"2022"},{"key":"10.1016\/j.ijpx.2025.100478_bb1235","series-title":"Sun Pharma Announces US FDA Approval for Generic Amphotericin B Liposome Injection","author":"Pharma","year":"2021"},{"key":"10.1016\/j.ijpx.2025.100478_bb1240","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1126\/science.1255288","article-title":"Polyunsaturated phospholipids facilitate membrane deformation and fission by endocytic proteins","volume":"345","author":"Pinot","year":"2014","journal-title":"Science"},{"key":"10.1016\/j.ijpx.2025.100478_bb1245","series-title":"Amphotericin B Liposome Preparation","author":"Proffitt","year":"1999"},{"key":"10.1016\/j.ijpx.2025.100478_bb1250","doi-asserted-by":"crossref","first-page":"1961","DOI":"10.1080\/14656566.2021.1953472","article-title":"The role of amikacin in the treatment of nontuberculous mycobacterial disease","volume":"22","author":"Raaijmakers","year":"2021","journal-title":"Expert. Opin. Pharmacother."},{"key":"10.1016\/j.ijpx.2025.100478_bb1255","doi-asserted-by":"crossref","first-page":"4279","DOI":"10.1021\/nn3008383","article-title":"Surface charge-switching polymeric nanoparticles for bacterial cell wall-targeted delivery of antibiotics","volume":"6","author":"Radovic-Moreno","year":"2012","journal-title":"ACS Nano"},{"key":"10.1016\/j.ijpx.2025.100478_bb1260","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1177\/1756283X17705328","article-title":"Update on the role of nanoliposomal irinotecan in the treatment of metastatic pancreatic cancer","volume":"10","author":"Rahman","year":"2017","journal-title":"Ther. Adv. Gastroenterol."},{"key":"10.1016\/j.ijpx.2025.100478_bb1265","doi-asserted-by":"crossref","first-page":"355","DOI":"10.1038\/s41579-025-01147-0","article-title":"Fungal biofilms in human health and disease","volume":"23","author":"Ramage","year":"2025","journal-title":"Nat. Rev. Microbiol."},{"key":"10.1016\/j.ijpx.2025.100478_bb1270","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13756-018-0370-9","article-title":"Risk factors for hospitalized patients with resistant or multidrug-resistant Pseudomonas aeruginosa infections: a systematic review and meta-analysis","volume":"7","author":"Raman","year":"2018","journal-title":"Antimicrob. Resist. Infect. Control"},{"key":"10.1016\/j.ijpx.2025.100478_bb1275","doi-asserted-by":"crossref","first-page":"2267","DOI":"10.3390\/molecules22122267","article-title":"Amikacin: uses, resistance, and prospects for inhibition","volume":"22","author":"Ramirez","year":"2017","journal-title":"Molecules"},{"key":"10.1016\/j.ijpx.2025.100478_bb1280","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1080\/10408347.2020.1803042","article-title":"A status update on pharmaceutical analytical methods of aminoglycoside antibiotic: Amikacin","volume":"52","author":"Raut","year":"2022","journal-title":"Crit. Rev. Anal. Chem."},{"key":"10.1016\/j.ijpx.2025.100478_bb1285","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1021\/acscentsci.1c00520","article-title":"Glycosylated polyene macrolides kill fungi via A conserved sterol sponge mechanism of action","volume":"7","author":"Revie","year":"2021","journal-title":"ACS Cent. Sci."},{"key":"10.1016\/j.ijpx.2025.100478_bb1290","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo-controlled trial","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpx.2025.100478_bb1295","doi-asserted-by":"crossref","first-page":"447","DOI":"10.1016\/j.ijpharm.2019.04.052","article-title":"Critical process parameters in manufacturing of liposomal formulations of amphotericin B","volume":"565","author":"Rivnay","year":"2019","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb1300","doi-asserted-by":"crossref","DOI":"10.3390\/pathogens6040062","article-title":"Liposomal and deoxycholate Amphotericin B formulations: effectiveness against biofilm infections of Candida spp","volume":"6","author":"Rodrigues","year":"2017","journal-title":"Pathogens"},{"key":"10.1016\/j.ijpx.2025.100478_bb1305","series-title":"The Immunoassay Handbook (Fourth Edition)","first-page":"945","article-title":"Chapter 9.22 - therapeutic drug monitoring (TDM)","author":"Routledge","year":"2013"},{"key":"10.1016\/j.ijpx.2025.100478_bb1310","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1007\/s13318-020-00669-7","article-title":"Population pharmacokinetic evaluation of amikacin liposome inhalation suspension in patients with treatment-refractory nontuberculous mycobacterial lung disease","volume":"46","author":"Rubino","year":"2021","journal-title":"Eur. J. Drug Metab. Pharmacokinet."},{"key":"10.1016\/j.ijpx.2025.100478_bb1315","doi-asserted-by":"crossref","DOI":"10.3390\/pharmaceutics8020018","article-title":"Current trends in development of liposomes for targeting bacterial biofilms","volume":"8","author":"Rukavina","year":"2016","journal-title":"Pharmaceutics"},{"key":"10.1016\/j.ijpx.2025.100478_bb1320","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/S0304-4165(99)00078-1","article-title":"Evaluation of the pulmonary and systemic immunogenicity of Fluidosomes, a fluid liposomal\u2013tobramycin formulation for the treatment of chronic infections in lungs","volume":"1428","author":"Sachetelli","year":"1999","journal-title":"Biochim. Biophys. Acta Gen. Subj."},{"key":"10.1016\/j.ijpx.2025.100478_bb1325","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/S0005-2736(99)00217-5","article-title":"Demonstration of a fusion mechanism between a fluid bactericidal liposomal formulation and bacterial cells","volume":"1463","author":"Sachetelli","year":"2000","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.ijpx.2025.100478_bb1330","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2022.122022","article-title":"Stability characterization for pharmaceutical liposome product development with focus on regulatory considerations: an update","volume":"624","author":"Sainaga Jyothi","year":"2022","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb1335","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.colsurfa.2017.02.084","article-title":"Preparation of liposomes: a comparative study between the double solvent displacement and the conventional ethanol injection\u2014from laboratory scale to large scale","volume":"524","author":"Sala","year":"2017","journal-title":"Colloids Surf. A Physicochem. Eng. Asp."},{"key":"10.1016\/j.ijpx.2025.100478_bb1340","doi-asserted-by":"crossref","first-page":"10","DOI":"10.1099\/jmm.0.045054-0","article-title":"Candida species: current epidemiology, pathogenicity, biofilm formation, natural antifungal products and new therapeutic options","volume":"62","author":"Sardi","year":"2013","journal-title":"J. Med. Microbiol."},{"key":"10.1016\/j.ijpx.2025.100478_bb1345","doi-asserted-by":"crossref","first-page":"369","DOI":"10.1016\/S0022-3565(24)29390-3","article-title":"In vivo synergistic interaction of liposome-coencapsulated gentamicin and ceftazidime","volume":"298","author":"Schiffelers","year":"2001","journal-title":"J. Pharmacol. Exp. Ther."},{"key":"10.1016\/j.ijpx.2025.100478_bb1350","series-title":"Medical Applications of Liposomes","first-page":"703","article-title":"CHAPTER 8.4 - Unilamellar liposomes for anticancer and antifungal therapy","author":"Schmidt","year":"1998"},{"key":"10.1016\/j.ijpx.2025.100478_bb1355","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.3389\/fphar.2019.01401","article-title":"Fusogenic Liposomes increase the Antimicrobial activity of Vancomycin against Staphylococcus aureus Biofilm","volume":"10","author":"Scriboni","year":"2019","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ijpx.2025.100478_bb1360","article-title":"Safety, tolerability, and pharmacokinetics of liposomal amphotericin B in immunocompromised pediatric patients","volume":"61","author":"Seibel Nita","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb1365","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1016\/j.jddst.2017.04.017","article-title":"Oral amphotericin B: the journey from bench to market","volume":"42","author":"Serrano","year":"2017","journal-title":"J. Drug Delivery Sci. Technol."},{"key":"10.1016\/j.ijpx.2025.100478_bb1370","doi-asserted-by":"crossref","first-page":"250","DOI":"10.2174\/2211738501999131118125018","article-title":"Amphotericin B formulations \u2013 the possibility of generic competition","volume":"1","author":"Serrano","year":"2013","journal-title":"Pharmaceut. Nanotechnol."},{"key":"10.1016\/j.ijpx.2025.100478_bb1375","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.addr.2020.07.002","article-title":"Liposomes: advancements and innovation in the manufacturing process","volume":"154-155","author":"Shah","year":"2020","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpx.2025.100478_bb1380","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.jcou.2018.12.011","article-title":"Generation of liposomes using a supercritical carbon dioxide eductor vacuum system: optimization of process variables","volume":"29","author":"Sharifi","year":"2019","journal-title":"J. CO\u2082 Util."},{"key":"10.1016\/j.ijpx.2025.100478_bb1385","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1016\/S0378-5173(97)00135-X","article-title":"Liposomes in drug delivery: progress and limitations","volume":"154","author":"Sharma","year":"1997","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb1390","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1016\/j.ijantimicag.2011.07.004","article-title":"Safety analysis of liposomal amphotericin B in adult patients: anaemia, thrombocytopenia, nephrotoxicity, hepatotoxicity and hypokalaemia","volume":"38","author":"Shigemi","year":"2011","journal-title":"Int. J. Antimicrob. Agents"},{"key":"10.1016\/j.ijpx.2025.100478_bb1395","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1007\/s40265-019-01095-z","article-title":"Amikacin liposome inhalation suspension: a review in mycobacterium avium complex lung disease","volume":"79","author":"Shirley","year":"2019","journal-title":"Drugs"},{"key":"10.1016\/j.ijpx.2025.100478_bb1400","doi-asserted-by":"crossref","DOI":"10.1016\/j.medmic.2023.100084","article-title":"Biofilms: Understanding the structure and contribution towards bacterial resistance in antibiotics","volume":"16","author":"Shree","year":"2023","journal-title":"Med. Microecol."},{"key":"10.1016\/j.ijpx.2025.100478_bb1405","doi-asserted-by":"crossref","first-page":"1397","DOI":"10.1128\/AAC.49.4.1397-1403.2005","article-title":"Differential expression of cytokines and chemokines in human monocytes induced by lipid formulations of amphotericin B","volume":"49","author":"Simitsopoulou","year":"2005","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb1410","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijbiomac.2024.135022","article-title":"Overcoming resistance: Chitosan-modified liposomes as targeted drug carriers in the fight against multidrug resistant bacteria-a review","volume":"278","author":"Singh","year":"2024","journal-title":"Int. J. Biol. Macromol."},{"key":"10.1016\/j.ijpx.2025.100478_bb1415","first-page":"306","article-title":"Lipid-based amphotericin b for the treatment of fungal infections. pharmacotherapy: the journal of human pharmacology and drug","volume":"19","author":"Slain","year":"1999","journal-title":"Therapy"},{"key":"10.1016\/j.ijpx.2025.100478_bb1420","doi-asserted-by":"crossref","DOI":"10.3390\/ijms18122688","article-title":"The consequences of being in an infectious biofilm: microenvironmental conditions governing antibiotic tolerance","volume":"18","author":"S\u00f8nderholm","year":"2017","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijpx.2025.100478_bb1425","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1080\/08982104.2017.1360345","article-title":"Fungal fatal attraction: a mechanistic review on targeting liposomal amphotericin B (AmBisome\u00ae) to the fungal membrane","volume":"27","author":"Soo Hoo","year":"2017","journal-title":"J. Liposome Res."},{"key":"10.1016\/j.ijpx.2025.100478_bb1430","doi-asserted-by":"crossref","DOI":"10.1016\/j.addr.2023.114969","article-title":"Reviving the interest in the versatile drug nystatin: a multitude of strategies to increase its potential as an effective and safe antifungal agent","volume":"199","author":"Sousa","year":"2023","journal-title":"Adv. Drug Deliv. Rev."},{"key":"10.1016\/j.ijpx.2025.100478_bb1435","doi-asserted-by":"crossref","first-page":"146","DOI":"10.1111\/myc.12585","article-title":"Efficacy and safety of amphotericin B lipid-based formulations\u2014A systematic review and meta-analysis","volume":"60","author":"Steimbach","year":"2017","journal-title":"Mycoses"},{"key":"10.1016\/j.ijpx.2025.100478_bb1440","doi-asserted-by":"crossref","first-page":"683","DOI":"10.1200\/JCO.1998.16.2.683","article-title":"Randomized comparative trial of pegylated liposomal doxorubicin versus bleomycin and vincristine in the treatment of AIDS-related Kaposi\u2019s sarcoma. International Pegylated Liposomal Doxorubicin Study Group","volume":"16","author":"Stewart","year":"1998","journal-title":"J. Clin. Oncol."},{"key":"10.1016\/j.ijpx.2025.100478_bb1445","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1007\/s40262-015-0250-x","article-title":"Clinical pharmacokinetics of inhaled antimicrobials","volume":"54","author":"Stockmann","year":"2015","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ijpx.2025.100478_bb1450","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40265-016-0538-7","article-title":"Liposomal Amphotericin B (AmBisome\u00ae): a review of the pharmacokinetics, pharmacodynamics, clinical experience and future directions","volume":"76","author":"Stone","year":"2016","journal-title":"Drugs"},{"key":"10.1016\/j.ijpx.2025.100478_bb1455","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1016\/S1461-5347(98)00007-8","article-title":"Liposomes: quo vadis?","volume":"1","author":"Storm","year":"1998","journal-title":"Pharm. Sci. Technol. Today"},{"key":"10.1016\/j.ijpx.2025.100478_bb1460","first-page":"544","article-title":"Amphotericin B release rate is the link between drug status in the liposomal bilayer and toxicity","volume":"17","author":"Svirkin","year":"2022","journal-title":"Asian J. Pharmaceut. Sci."},{"key":"10.1016\/j.ijpx.2025.100478_bb1465","doi-asserted-by":"crossref","first-page":"8201","DOI":"10.1039\/C4TB01110D","article-title":"Phospholipase A2-responsive antibiotic delivery via nanoparticle-stabilized liposomes for the treatment of bacterial infection","volume":"2","author":"Thamphiwatana","year":"2014","journal-title":"J. Mater. Chem. B"},{"key":"10.1016\/j.ijpx.2025.100478_bb1470","doi-asserted-by":"crossref","first-page":"649","DOI":"10.2165\/00003088-200645070-00002","article-title":"Pharmacokinetic\/pharmacodynamic profile of voriconazole","volume":"45","author":"Theuretzbacher","year":"2006","journal-title":"Clin. Pharmacokinet."},{"key":"10.1016\/j.ijpx.2025.100478_bb1475","doi-asserted-by":"crossref","first-page":"1598","DOI":"10.1007\/s13346-021-00921-w","article-title":"Nano-fats for bugs: the benefits of lipid nanoparticles for antimicrobial therapy","volume":"11","author":"Thorn","year":"2021","journal-title":"Drug Deliv. Transl. Res."},{"key":"10.1016\/j.ijpx.2025.100478_bb1480","first-page":"88","article-title":"Liposomes as sterile preparations and limitations of sterilisation techniques in liposomal manufacturing","volume":"8","author":"Toh","year":"2013","journal-title":"Asian J. Pharmaceut. Sci."},{"key":"10.1016\/j.ijpx.2025.100478_bb1485","doi-asserted-by":"crossref","first-page":"2405","DOI":"10.1002\/jps.21179","article-title":"Amphotericin B Formulations and Drug Targeting","volume":"97","author":"Torrado","year":"2008","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2025.100478_bb1490","series-title":"Expert Committee Approves Endotoxin Testing Using Non-animal Derived Reagents","author":"USP","year":"2024"},{"key":"10.1016\/j.ijpx.2025.100478_bb1495","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2023.122739","article-title":"Colistin- and amikacin-loaded lipid-based drug delivery systems for resistant gram-negative lung and wound bacterial infections","volume":"635","author":"Vairo","year":"2023","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb1500","doi-asserted-by":"crossref","first-page":"6368","DOI":"10.1021\/ie060055v","article-title":"Solubility of antibiotics in different solvents. 1. Hydrochloride forms of tetracycline, moxifloxacin, and ciprofloxacin","volume":"45","author":"Varanda","year":"2006","journal-title":"Ind. Eng. Chem. Res."},{"key":"10.1016\/j.ijpx.2025.100478_bb1505","doi-asserted-by":"crossref","first-page":"2263","DOI":"10.1002\/jbm.a.36984","article-title":"Anidulafungin liposome nanoparticles exhibit antifungal activity against planktonic and biofilm","volume":"108","author":"Vera-Gonz\u00e1lez","year":"2020","journal-title":"J. Biomed. Mater. Res. A"},{"key":"10.1016\/j.ijpx.2025.100478_bb1510","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1093\/cid\/civ885","article-title":"Azole resistance in Aspergillus fumigatus: can we retain the clinical use of mold-active antifungal azoles?","volume":"62","author":"Verweij","year":"2016","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpx.2025.100478_bb1515","first-page":"1391","article-title":"Challenges facing sterilization and depyrogenation of nanoparticles: Effects on structural stability and biomedical applications. Nanomedicine: Nanotechnology","volume":"10","author":"Vetten","year":"2014","journal-title":"Biol. Med."},{"key":"10.1016\/j.ijpx.2025.100478_bb1520","doi-asserted-by":"crossref","first-page":"417","DOI":"10.2147\/nano.2006.1.4.417","article-title":"Optimizing efficacy of amphotericin B through nanomodification","volume":"1","author":"Vyas","year":"2006","journal-title":"Int. J. Nanomedicine"},{"key":"10.1016\/j.ijpx.2025.100478_bb1525","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1016\/j.ijpharm.2003.08.017","article-title":"Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages","volume":"269","author":"Vyas","year":"2004","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb1530","first-page":"9","article-title":"The viscoelastic properties of the fungal cell wall allow traffic of AmBisome as intact liposome vesicles","author":"Walker","year":"2018","journal-title":"mBio"},{"key":"10.1016\/j.ijpx.2025.100478_bb1535","doi-asserted-by":"crossref","first-page":"1578","DOI":"10.1002\/jps.23508","article-title":"Physicochemical aspects of the coformulation of colistin and azithromycin using liposomes for combination antibiotic therapies","volume":"102","author":"Wallace","year":"2013","journal-title":"J. Pharm. Sci."},{"key":"10.1016\/j.ijpx.2025.100478_bb1540","doi-asserted-by":"crossref","first-page":"2391","DOI":"10.1128\/AAC.42.9.2391","article-title":"Safety, tolerance, and pharmacokinetics of a small unilamellar liposomal formulation of amphotericin B (AmBisome) in neutropenic patients","volume":"42","author":"Walsh","year":"1998","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb1545","doi-asserted-by":"crossref","first-page":"764","DOI":"10.1056\/NEJM199903113401004","article-title":"Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group","volume":"340","author":"Walsh","year":"1999","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.ijpx.2025.100478_bb1550","doi-asserted-by":"crossref","first-page":"3487","DOI":"10.1128\/AAC.45.12.3487-3496.2001","article-title":"Safety, tolerance, and pharmacokinetics of high-dose liposomal amphotericin B (AmBisome) in patients infected with Aspergillus species and other filamentous fungi: maximum tolerated dose study","volume":"45","author":"Walsh","year":"2001","journal-title":"Antimicrob. Agents Chemother."},{"key":"10.1016\/j.ijpx.2025.100478_bb1555","doi-asserted-by":"crossref","DOI":"10.3390\/molecules29235659","article-title":"Effects of different concentrations of AmB on the unsaturated phospholipid-cholesterol membrane using the langmuir monolayer and liposome models","volume":"29","author":"Wang","year":"2024","journal-title":"Molecules"},{"key":"10.1016\/j.ijpx.2025.100478_bb1560","doi-asserted-by":"crossref","DOI":"10.1002\/wnan.1822","article-title":"Intelligent design of polymersomes for antibacterial and anticancer applications","volume":"14","author":"Wang","year":"2022","journal-title":"WIREs Nanomed. Nanobiotechnol."},{"key":"10.1016\/j.ijpx.2025.100478_bb1565","doi-asserted-by":"crossref","first-page":"2585","DOI":"10.1016\/j.apsb.2021.04.010","article-title":"Delivery strategies of amphotericin B for invasive fungal infections","volume":"11","author":"Wang","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"key":"10.1016\/j.ijpx.2025.100478_bb1570","doi-asserted-by":"crossref","first-page":"2626","DOI":"10.1111\/jam.15053","article-title":"Liposome as a delivery system for the treatment of biofilm-mediated infections","volume":"131","author":"Wang","year":"2021","journal-title":"J. Appl. Microbiol."},{"key":"10.1016\/j.ijpx.2025.100478_bb1575","doi-asserted-by":"crossref","first-page":"54580","DOI":"10.1039\/C5RA06424D","article-title":"Molecular mechanisms for the adhesion of chitin and chitosan to montmorillonite clay","volume":"5","author":"Wang","year":"2015","journal-title":"RSC Adv."},{"key":"10.1016\/j.ijpx.2025.100478_bb1580","doi-asserted-by":"crossref","first-page":"1511","DOI":"10.1021\/mp300143n","article-title":"Toward understanding of toxic side effects of a polyene antibiotic amphotericin B: fluorescence spectroscopy reveals widespread formation of the specific supramolecular structures of the drug","volume":"9","author":"Wasko","year":"2012","journal-title":"Mol. Pharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb1585","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/S0005-2736(98)00238-7","article-title":"Target-cell specificity of fusogenic liposomes: membrane fusion-mediated macromolecule delivery into human blood mononuclear cells","volume":"1416","author":"Watabe","year":"1999","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.ijpx.2025.100478_bb1590","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1586\/17476348.2014.918507","article-title":"Inhaled liposomal amikacin","volume":"8","author":"Waters","year":"2014","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.ijpx.2025.100478_bb1595","article-title":"Antibiotic treatment for nontuberculous mycobacteria lung infection in people with cystic fibrosis","volume":"12","author":"Waters","year":"2016","journal-title":"Cochrane Database Syst. Rev."},{"key":"10.1016\/j.ijpx.2025.100478_bb1600","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1016\/0005-2736(78)90130-X","article-title":"Control of the structure and fluidity of phosphatidylglycerol bilayers by pH titration","volume":"510","author":"Watts","year":"1978","journal-title":"Biochim. Biophys. Acta Biomembr."},{"key":"10.1016\/j.ijpx.2025.100478_bb1605","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1089\/jamp.2008.0693","article-title":"A gamma scintigraphy study to investigate lung deposition and clearance of inhaled amikacin-loaded liposomes in healthy male volunteers","volume":"22","author":"Weers","year":"2009","journal-title":"J. Aerosol. Med. Pulm. Drug Deliv."},{"key":"10.1016\/j.ijpx.2025.100478_bb1610","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1128\/CMR.00101-15","article-title":"Inhaled Antibiotics for Gram-negative respiratory Infections","volume":"29","author":"Wenzler","year":"2016","journal-title":"Clin. Microbiol. Rev."},{"key":"10.1016\/j.ijpx.2025.100478_bb1615","doi-asserted-by":"crossref","first-page":"794","DOI":"10.1007\/s100960050189","article-title":"Kinetics and toxicity of liposomal and conventional amikacin in a patient with multidrug-resistant tuberculosis","volume":"17","author":"Whitehead","year":"1998","journal-title":"Eur. J. Clin. Microbiol. Infect. Dis."},{"key":"10.1016\/j.ijpx.2025.100478_bb1620","series-title":"Guidelines for Diagnosing, Preventing and Managing Cryptococcal Disease among Adults, Adolescents and Children Living with HIV","first-page":"1","author":"WHO","year":"2022"},{"key":"10.1016\/j.ijpx.2025.100478_bb1625","series-title":"WHO Fungal Priority Pathogens List to Guide Research, Development and Public Health Action","author":"WHO","year":"2022"},{"key":"10.1016\/j.ijpx.2025.100478_bb1630","series-title":"WHO Medically Important Antimicrobial List (MIA List): 7th Revision \u2013 Draft for External Discussion, Geneva, Switzerland","author":"WHO","year":"2023"},{"key":"10.1016\/j.ijpx.2025.100478_bb1635","series-title":"World Leaders Commit to Decisive Action on Antimicrobial Resistance","author":"WHO","year":"2024"},{"key":"10.1016\/j.ijpx.2025.100478_bb1640","series-title":"Notes on the Design of Bioequivalence Study: Amphotericin B (liposomal)","author":"WHO","year":"2025"},{"key":"10.1016\/j.ijpx.2025.100478_bb1645","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/S1473-3099(22)00811-8","article-title":"Incidence of infection with multidrug-resistant Gram-negative bacteria and vancomycin-resistant enterococci in carriers: a systematic review and meta-regression analysis","volume":"23","author":"Willems","year":"2023","journal-title":"Lancet Infect. Dis."},{"key":"10.1016\/j.ijpx.2025.100478_bb1650","doi-asserted-by":"crossref","first-page":"295","DOI":"10.1016\/S0939-6411(97)00058-1","article-title":"Long term stability of freeze-dried, lyoprotected doxorubicin liposomes","volume":"43","author":"van Winden","year":"1997","journal-title":"Eur. J. Pharm. Biopharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb1655","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1086\/514704","article-title":"Lipid formulations of amphotericin B: clinical efficacy and toxicities","volume":"27","author":"Wong-Beringer","year":"1998","journal-title":"Clin. Infect. Dis."},{"key":"10.1016\/j.ijpx.2025.100478_bb1660","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2019.118915","article-title":"Inhalable liposomal powder formulations for co-delivery of synergistic ciprofloxacin and colistin against multi-drug resistant gram-negative lung infections","volume":"575","author":"Yu","year":"2020","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb1665","doi-asserted-by":"crossref","DOI":"10.3390\/ijms24043110","article-title":"Bacterial Infections and cancer: exploring this association and its implications for cancer patients","volume":"24","author":"Yusuf","year":"2023","journal-title":"Int. J. Mol. Sci."},{"key":"10.1016\/j.ijpx.2025.100478_bb1670","series-title":"Liposomes: Methods and Protocols","first-page":"17","article-title":"Thin-Film Hydration Followed by Extrusion Method for Liposome Preparation","author":"Zhang","year":"2017"},{"key":"10.1016\/j.ijpx.2025.100478_bb1675","doi-asserted-by":"crossref","first-page":"915","DOI":"10.3389\/fmicb.2018.00915","article-title":"Amikacin Liposome Inhalation Suspension (ALIS) penetrates non-tuberculous mycobacterial biofilms and enhances amikacin uptake into macrophages","volume":"9","author":"Zhang","year":"2018","journal-title":"Front. Microbiol."},{"key":"10.1016\/j.ijpx.2025.100478_bb1680","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1080\/1061186X.2019.1681434","article-title":"Antimicrobial lipids in nano-carriers for antibacterial delivery","volume":"28","author":"Zhang","year":"2020","journal-title":"J. Drug Target."},{"key":"10.1016\/j.ijpx.2025.100478_bb1685","doi-asserted-by":"crossref","DOI":"10.1016\/j.ijpharm.2025.125202","article-title":"Navigating translational research in nanomedicine: A strategic guide to formulation and manufacturing","volume":"671","author":"Zhang","year":"2025","journal-title":"Int. J. Pharm."},{"key":"10.1016\/j.ijpx.2025.100478_bb1690","doi-asserted-by":"crossref","first-page":"737","DOI":"10.1080\/17476348.2021.1875821","article-title":"Amikacin liposome inhalation suspension as a treatment for patients with refractory mycobacterium avium complex lung infection","volume":"15","author":"Zhang","year":"2021","journal-title":"Expert Rev. Respir. Med."},{"key":"10.1016\/j.ijpx.2025.100478_bb1695","doi-asserted-by":"crossref","DOI":"10.1038\/s41598-017-11847-0","article-title":"Biomimetically engineered Amphotericin B nano-aggregates circumvent toxicity constraints and treat systemic fungal infection in experimental animals","volume":"7","author":"Zia","year":"2017","journal-title":"Sci. Rep."},{"key":"10.1016\/j.ijpx.2025.100478_bb1700","doi-asserted-by":"crossref","first-page":"1591","DOI":"10.1023\/A:1018916518515","article-title":"Sterilization of liposomes by heat treatment","volume":"10","author":"Zuidam","year":"1993","journal-title":"Pharm. Res."},{"key":"10.1016\/j.ijpx.2025.100478_bb1705","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1016\/0005-2736(95)00180-5","article-title":"Physical (in) stability of liposomes upon chemical hydrolysis: the role of lysophospholipids and fatty acids","volume":"1240","author":"Zuidam","year":"1995","journal-title":"Biochim. Biophys. Acta Biomembr."}],"container-title":["International Journal of Pharmaceutics: X"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259015672500163X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S259015672500163X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,7,28]],"date-time":"2026-07-28T03:48:52Z","timestamp":1785210532000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S259015672500163X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,6]]},"references-count":341,"alternative-id":["S259015672500163X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijpx.2025.100478","relation":{},"ISSN":["2590-1567"],"issn-type":[{"value":"2590-1567","type":"print"}],"subject":[],"published":{"date-parts":[[2026,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Liposomal antimicrobials in the fight against bacterial and fungal pathogens: Clinical successes and development challenges","name":"articletitle","label":"Article Title"},{"value":"International Journal of Pharmaceutics: X","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijpx.2025.100478","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100478"}}